HRMY
Harmony Biosciences Holdings, Inc.
$36.83
+0.70
(+1.94%)
Mkt Cap
2.14B
Volume
850,295
52W Range
25.9-43.49
Sector
Healthcare
Beta
1.01
EPS (TTM)
3.13 USD
P/E Ratio
11.77
Revenue (TTM)
959.90M USD
Rev Growth (5Y)
+40.3%
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
What we estimate one share is worth
$121.29
Undervalued
strong signal
69.6% below fair value
Modeled from cash flows & growth.
AlphaQuality · Grade
How strong & durable the business is
A-
Platform & Compounding FCF
85.5 / 100 composite
A platform business that compounds free cash flow — graded A–F vs. similar companies.
Company Description
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 868.45M | 714.73M | 582.02M | 437.86M | 305.44M | 159.74M | 6.00M | 0 |
| Net Income | 158.69M | 145.49M | 128.85M | 181.47M | 34.60M | (36.94M) | (151.98M) | (39.90M) |
| EPS | 2.76 | 2.56 | 2.17 | 3.07 | 0.60 | -1.12 | -2.94 | -1.42 |
| Free Cash Flow | 347.89M | 218.67M | 219.07M | 144.29M | 98.26M | (4.99M) | (75.58M) | (40.14M) |
| FCF / Share | 6.05 | 3.84 | 3.68 | 2.44 | 1.71 | -0.09 | -1.19 | -0.82 |
| Operating CF | 348.20M | 219.82M | 219.39M | 144.47M | 98.56M | (2.98M) | (75.44M) | (38.80M) |
| Total Assets | 1.27B | 999.20M | 811.45M | 673.87M | 433.44M | 427.07M | 106.70M | 89.28M |
| Total Debt | 239.58M | 181.41M | 193.57M | 191.65M | 195.74M | 194.25M | 97.95M | 324.20M |
| Cash & Equiv | 752.50M | 453.00M | 311.66M | 243.78M | 234.31M | 228.63M | 24.46M | 83.52M |
| Book Value | 870.22M | 659.15M | 466.99M | 402.84M | 186.51M | 97.18M | (11.59M) | 81.53M |
| Return on Equity | 0.18 | 0.22 | 0.28 | 0.45 | 0.19 | -0.38 | N/A | -0.49 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 261.28M | 215.39M | 243.78M | 239.46M | 200.49M | 184.73M | 201.27M | 186.04M | 172.81M | 154.62M | 168.41M | 160.27M |
| Net Income | 75.43M | 32.49M | 22.49M | 50.87M | 39.78M | 45.56M | 49.48M | 46.09M | 11.59M | 38.33M | 26.61M | 38.46M |
| EPS | 1.30 | 0.56 | 0.39 | 0.88 | 0.69 | 0.80 | 0.87 | 0.81 | 0.20 | 0.68 | 0.46 | 0.64 |
| Free Cash Flow | 92.43M | 27.76M | 126.04M | 108.66M | 79.32M | 33.86M | 75.05M | 70.50M | 41.98M | 31.14M | 76.56M | 63.10M |
| FCF / Share | 1.60 | 0.48 | 2.19 | 1.86 | 1.38 | 0.59 | 1.31 | 1.24 | 0.74 | 0.55 | 1.31 | 1.05 |
| Operating CF | 92.43M | 27.76M | 126.15M | 108.73M | 79.33M | 33.99M | 75.56M | 70.50M | 42.62M | 31.14M | 76.67M | 63.10M |
| Total Assets | 1.37B | 1.27B | 1.27B | 1.21B | 1.11B | 1.06B | 999.20M | 928.13M | 858.38M | 846.99M | 811.45M | 777.77M |
| Total Debt | 153.96M | 206.51M | 239.58M | 169.73M | 173.37M | 177.46M | 181.41M | 185.24M | 189.06M | 193.06M | 196.09M | 199.72M |
| Cash & Equiv | 549.77M | 589.40M | 752.50M | 647.00M | 546.05M | 489.00M | 453.00M | 387.37M | 317.30M | 332.98M | 311.66M | 324.60M |
| Book Value | 999.24M | 910.35M | 870.22M | 835.12M | 773.08M | 720.52M | 659.15M | 596.80M | 538.58M | 515.39M | 466.99M | 481.33M |
| Return on Equity | 0.08 | 0.04 | 0.03 | 0.06 | 0.05 | 0.06 | 0.08 | 0.08 | 0.02 | 0.07 | 0.06 | 0.08 |
HRMY News
HRMY or ARGX: Which Is the Better Value Stock Right Now?
Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now?
Revisiting Former Stock Picks Marriott, Logitech, Harmony Biosciences
Harmony Biosciences: A Cash Machine With A Patent Ruling Hanging Over It
Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026
Harmony Biosciences (NASDAQ:HRMY) Earns “Buy” Rating from Needham & Company LLC
HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth?
Why Harmony Biosciences Stock Got Mashed on Monday
Harmony Biosciences (NASDAQ:HRMY) Shares Gap Down – What’s Next?
Head to Head Review: Harmony Biosciences (NASDAQ:HRMY) versus PainReform (NASDAQ:PRFX)